secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001104659-26-018858
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences Q4 revenue $243.8M (+21% YoY); guides WAKIX to $1B+ in 2026
-------------------------------------------------------------------------------

- Full-year 2025 WAKIX revenue $868.5M, up 22% YoY; Q4 GAAP EPS $0.38, adjusted EPS $0.57.
- 2026 net revenue guidance for WAKIX: $1.0-1.04B, targeting blockbuster status.
- FDA approved pediatric cataplexy indication for WAKIX on Feb 13; commercial launch underway.
- Settled with 3 additional generic filers, now 6 of 7; generics entry no earlier than March 2030 if pediatric exclusivity granted.
- Pitolisant GR NDA submission on track for Q2 2026; orexin-2 agonist Phase 1 data expected mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000110465926018858/0001104659-26-018858-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000110465926018858/hrmy-20260224x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-018858

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer